Prescribing antiplatelet drugs in primary care

MeReC Bulletin

Volumn 15, Issue 6, 2004, Pages 21-24

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; ESOMEPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG RELEASE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PEPTIC ULCER BLEEDING; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; RASH; REVIEW; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

EID: 28244474507     PISSN: 14655659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Patrono C, Coller B, Fitzgerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness and side effects. Chest 2004;126:234S-64S.
3. Serebruany VL, Steinbuhl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of asprin in 192,036 patients enrolled in 31 randomised controlled trials. Am J Cardiol 2005;95:1218-22.
4. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;142:1-13.
5. Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD001820. DOI: 10.1002/14651858.CD001820.
6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
7. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
8. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
9. Summary of Product Characteristics. Plavix. Available at: www.medicines.org.uk. Accessed 23/06/2005.
10. Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Circulation 2003;108:1682-7.
11. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
12. Mehta SM, Yusuf S, Peters RJG, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
13. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J 2004;25:720-2.
14. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence. Ann Intern Med 2002;136:161-72.
15. Ridker PM, Cook NR, Lee I-M, et al. A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
16. National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. Technology Appraisal 90. May 2005. Available at: www.nice.org.uk. Accessed 25/06/05.
17. National Institute for Clinical Excellence. Clopidogrel in the treatment of non-ST segment-elevation acute coronary syndrome. Technology Appraisal 80. July 2004. Available at: www.nice.org.uk. Accessed 25/06/05.
18. PRODIGY Guidance: Coronary heart disease risk - identification and management. September 2004. Available at: www.prodigy.nhs.uk. Accessed 25/06/05.
19. British National Formulary No. 49. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2005.
20. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) 2004. Available at www.acc.org/clinical/guidelines/stemi/index.pdf. Accessed 21/06/05.
21. Jain M, Rosenberg M. Review: aspirin reduces CAD events in people with no history of cardiovascular disease, but it increases gastrointestinal bleeding. EBM 2002;7:111.
22. Chan FK, Ching JYL, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44.
23. Anon. Aspirin + PPI safer than clopidogrel if history of GI bleed. InfoPOEM Inc 2004. Available at: www.infopoems.com/infopoems/showPOEM.cfm?ID= 70303. Accessed 23/06/05.
24. Anon. Which prophylactic aspirin? DTB 1997;35:7-8.